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Abstract
Introduction: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report
prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community
cohort in Lesotho.
Methods: We calculated changes in CrCl from baseline for patients initiated on TDF at 6 and 12 months and the proportion
of patients initiated on TDF who developed renal impairment. Screening algorithms were developed using risk factors
determined by multivariate analysis.
Results: Among 933 adults for whom baseline creatinine was available, 176 (18.9%) presented with a baseline CrCl ,50 ml/
min. Renal function improved during follow-up. 19 patients who developed renal toxicity during follow up remained on
TDF; renal function improved (CrCl$50 ml/min) in all but 3 of these patients. Among 15 patients with a baseline CrCl
,50 ml/min were started in error, none developed severe renal impairment.
Conclusion: In this setting TDF-associated renal toxicity is rare and mainly transient. Further studies to assess TDF safety at
lower CrCl thresholds are warranted.
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Introduction
In 2009 the World Health Organisation revised its guidelines
for antiretroviral therapy (ART) in resource-limited settings to
recommend replacing stavudine with either tenofovir or zidovu-
dine [1]. In randomized trials tenofovir has demonstrated
comparable efficacy when compared with other first-line regimens
containing stavudine, zidovudine or abacavir [2–4], and has the
additional advantage of low toxicity and availability as a once-
daily, fixed-dose generic formulation [5]. However, concerns
about potential nephrotoxicity have led to recommendations for
close clinical monitoring. Clinical detection of renal impairment is
difficult in resource-limited settings. Early stages of renal
dysfunction are assessed through laboratory monitoring of
creatinine and glomerular filtration rate is calculated using either
the Cockcroft Gault formula or the modification of diet in renal
disease (MDRD) calculation.
Current international guidelines contraindicate TDF use when
creatinine clearance (CrCl) falls below 50 ml/min unless dose
reductions are made [6] and acknowledging the potential for
nephrotoxicity, six-monthly monitoring of renal function is
recommended by national guidelines [7]. If TDF is to be
implemented in resource-limited settings where numbers requiring
antiretroviral therapy are high but access to laboratory services are
scarce, these monitoring protocols may need to be further
simplified.
In this paper we report on program performance, early toxicity
outcomes, prevalence of abnormal renal function at baseline, and
factors associated with abnormal renal function from a community
cohort in Lesotho.
Methods
Study setting
Me ´decins Sans Frontie `res (MSF) and the Ministry of Health and
Social Welfare established a decentralized HIV/AIDS care and
treatment programme at the primary health care level in Scott
Health Service Area, Lesotho in 2006. ART services are provided
across 14 primary care health centres and one district hospital,
each staffed by nurses who initiate and manage ART, with
complicated cases referred to the district hospital [8]. National
guidelines recommend prescribing TDF to all non-pregnant adults
above 18 years of age with adequate renal function, defined as a
CrCl .50 ml/min calculated using the Cockcroft-Gault formula.
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All adults initiating antiretroviral therapy from 1 January 2008
to 31 December 2008 and who had a baseline serum creatinine
were included in the analysis. Data were extracted from clinic
registers and medical notes by a team of three clinicians, entered
into an Access database then exported into STATA (version 11)
for analysis.
Creatinine clearance and renal function
Creatinine measurements were performed in the district
hospital laboratory. Crcl was calculated using the Cockcroft Gault
formula using weight taken on the same day that creatinine
measurements were done but without adjusting for body surface
area, consistent with guidelines for resource-limited settings.
Baseline renal function was categorized according to CrCl as
follows: normal (CrCl $90 ml/min), mild (CrCl 60–89 ml/min),
moderate (CrCl 30–59 ml/min) and severe renal impairment
(CrCl ,30 ml/min). Baseline renal function was further catego-
rized into CrCl ,50 ml/min and $50 ml/min. CrCl results that
had been calculated and documented by the nurses were extracted
from the clinical records.
Data analysis
The proportion of creatinine measurements performed accord-
ing to the monitoring protocol was calculated along with the
proportion of CrCl documented in the notes. Agreement between
nurse- and computer-calculated CrCl was determined by strati-
fying the nurse-calculated CrCl as less or greater than 10%
different from the computer-calculated CrCl. Improvement over
time was assessed by the x
2 test.
Baseline characteristics were described using medians and
interquartile ranges (IQRs) for continuous variables and counts
and percentages for categorical variables. Baseline characteristics
were compared for patients starting TDF correctly and those started
in error: continuous variables were assessed for skew and as all
demonstrated non-normality they were compared using the
Wilcoxon rank-sum test while proportions were compared using
the Fisher’s Exact test. The prevalence of baseline renal insufficiency
(CrCl,50 ml/min) wasdetermined and univariate andmultivariate
logistic regression models were built to calculate crude and adjusted
oddsratioscomparingCrCl,50 ml/minversusCrCl$50 ml/min.
Multivariate models were built through backwards elimination to
determine risk factors for reduced CrCl. Screening algorithms with
different thresholds were developed using risk factors determined in
the multivariate model. The number of patients needing screening
and the number of cases with a CrCl ,50 ml/min missed were
calculated for each of thesealgorithms. Median change in CrCl from
baseline for those initiated on TDF was calculated at 6 and 12
months. All reported P values are exact and two-tailed, and for each
analysis a P-value ,0.05 was considered significant.
The analysis was approved by the independent Ethics Review
Board of Me ´decins Sans Frontie `res [9]. Individual patient consent
was not sought because the analysis was based on routine clinical
data, consistent with norms of the Ethics Review Board for
secondary analyses. All patient information was entered into the
database using coded identification numbers, and no information
that could reveal patient identity was entered into the database.
Results
Program performance
566 patients with a baseline CrCl$50 ml/min were started on
TDF. Creatinine monitoring was performed in 57.1% of patients
(298/522) still in care at six months, 47.3% of patients (192/406)
still in care at 12 months, and 26.6% of patients (25/94) patients
still in care at 18 months. A total of 2301 creatinine measurements
were performed at baseline and during follow-up. CrCl was not
documented for more than one third of measurements (824, 36%).
The overall median difference between nurse- and formula-
calculated CrCl was 1 ml/min (IQR 0–2). However, 268 nurse-
calculated CrCls were outside 610% of the computer-calculated
CrCls. There was a significant improvement of nurse-calculated
CrCls over time. 27.3% of nurse-calculated CrCls were outside
610% range of the computer-calculated CrClS in the first half
year, 20.6% in the second half year, 13.7% in the third half year
and 9.7% in the last half year (p,0.01).
Baseline characteristics
Baseline creatinine was measured for 933 adults prior to
initiating ART. Median age was 40.6 years (IQR 32.6–50.4), the
majority (62.5%) were women and median CD4 count was 209
cells/uL (IQR 119–282). 135 (14.5%) presented with normal renal
function, 475 (50.9%) with mild renal impairment, 311 (33.3%)
with moderate impairment, and 12 (1.3%) with severe impair-
ment. Baseline characteristics of patients who were initiated on
tenofivir (n=566) are summarized in Table 1.
Risk factors associated with reduced baseline creatinine
clearance
A total of 176 (18.9%) presented with a baseline CrCl ,50 ml/
min, the threshold at which TDF would be contraindicated.
Univariate analysis showed that CrCl ,50 ml/min was more
likely in women, older patients, and patients with more severe
immunosuppression (Table 2). Tuberculosis at the time of ART
Table 1. Baseline characteristics of patients started on Tenofovir.
Variable
Patients started on TDF despite
creatinine clearance ,50 ml/min N=15
Patients started on TDF with creatinine
clearance .50 ml/min N=566 p
Baseline creatinine clearance 45 (36–47) 73 (63–84) –
Age (median, IQR) 50.7 (44.4–56.7) 38.9 (32.4–48.0) 0.0002
Men (N, %) 3 (20.0%) 271 (47.9%) 0.04
CD4 (median, IQR) 240 (209–297) 211 (120–282) 0.20
TB at ART initiation (N, %) 2 (13.3%) 102 (18.0%) 1.0
WHO stage 4 (N, %) 1 (6.7%) 44 (7.8%) 1.0
Opportunistic infection at ART initiation 0 (0%) 22 (3.9%) 1.0
doi:10.1371/journal.pone.0017609.t001
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baseline renal function. Mutivariate analysis showed that patients
aged $50 years were 11.4 times more likely to have a
CrCl,50 ml/min compared to patients aged ,30 years (95%
confidence interval (CI) 5.44–23.98) Men were 0.36 less likely than
women to have a CrCl ,50 ml/min (95%CI 0.23–0.55). Having
a CD4 count of ,50 cells/uL increased the risk of renal
insufficiency by 2.35 times compared to having a CD4 count
.200 cells/uL (95%CI 1.33–4.16).
Screening algorithms
Using these associations, we developed algorithms for baseline
screening of creatinine. The aim of the algorithms, which are
summarized in Table 3, were to demonstrate the numbers needing
to be screened versus the proportion of cases with CrCl ,50 ml/
min that would be missed by their application. Scenarios 3 and 5
would both mean that 25% of the cohort would be excluded from
screening but only 8% (14) of cases with baseline CrCl ,50 ml/
min would be undetected – 1.5% of the total cohort. Only 2 of the
undetected cases had a CrCl ,40 ml/min.
Renal function during follow-up and toxicity
Renal function improved during follow-up with a median
change in CrCl of +5 ml/min (IQR 8–20) at 6 months (120–240
days) and +7 ml/min (IQR -3-22) at 12 months (240–480 days).
31 (5.5%) of the 566 patients initiated on TDF with a baseline
CrCl$50 ml/ml developed toxicity (CrCL ,50 ml/min) during
follow-up. The majority of these patients (28 of 31) had a drop in
CrCl of less than ,10 ml/min below the 50 ml/min threshold.
Only 1 patient developed severe renal impairment (CrCl,30 ml/
min). 29 of the 31 patients with renal toxicity during follow up
remained in care, 1 patient was lost to follow-up and 1 died. The
death was not related to TDF toxicity. A third of patients with
renal impairment during follow-up (10 out of 29) were switched
from a TDF-containing regimen to an AZT-containing regimen
according to national guidelines. 19 remained on TDF despite
renal impairment; among these, 17 had a CrCl of 40–50 ml/min
and 2 had a CrCl of 30–40 ml/min at the time of renal
impairment. Renal function improved (CrCl$50 ml/min) in all
but 3 of these patients who remained on TDF.
15 patients were started in error on TDF despite having a
baseline CrCl ,50 ml/min (range 30–49). When compared to
patients who were started correctly on TDF, this group comprised
more women, and older patients (p,0.05) (Table 1), consistent
with the risk factors for low CrCl identified in multivariate
analysis. In five cases the calculation was not performed, 6 were
calculated incorrectly and the remaining 4 were started on TDF
despite a correct CrCl calculation being performed. Among these
patients, 3 were subsequently switched to AZT. Among those who
remained on TDF, 6 experienced an improvement of renal
function (CrCl$50 ml/min), 3 had a stable renal function (CrCl
40–50 ml/min) and 3 had no further creatinine documented.
None of these patients developed severe renal impairment
(CrCl,30 ml/min).
Discussion
In our study TDF was contraindicated in almost a fifth (18.9%)
of patients due to a baseline CrCl of ,50 ml/min. Implementing
the protocol for CrCl follow-up both in terms of samples being
drawn and correct calculation of CrCl in this setting was a
challenge. Despite this, and the high median age of this cohort,
documented toxicity was rare and mild.
Reported baseline renal function among HIV-infected patients in
African settings is variable. Prevalence of mild renal insufficiency
ranges from 24% in Zambia to 41.2% in Malawi, moderate
insufficiency ranges from 7.6% in Zambia to 21.8% in Malawi, and
severe insufficiency was under 2% in all studies [10–12]. Estimating
the proportion of those who are not eligible for TDF according to
currently accepted criteria of CrCl ,50 ml/min is important for
estimating the procurement needs for alternative regimens. For
settingswhere TDF-initiation withoutbaseline screening is proposed,
consideration of the proportion with baseline renal impairment
should be given to assess the degree of risk of potential toxicity.
Table 2. Variables associated with creatinine clearance ,50 ml/min (N=933).
Variable
Creatinine Clearance
.50 N=757
Creatinine Clearance
,50 N=176 Unadjusted OR Adjusted OR
Age (years) #30 147 (19.4) 10 (5.7) 1 1
31–35 144 (19.0) 15 (8.5) 1.53 (0.67–3.52) 1.76 (0.73–4.24)
36-40 119 (15.7) 10 (5.7) 1.24 (0.50–3.07) 1.73 (0.67–4.45)
41-50 196 (25.9) 55 (31.3) 4.13 (2.03–8.36) 5.08 (2.40–10.74)
.50 151 (20.0) 86 (48.9) 8.37 (4.19–16.74) 11.42 (5.44–23.98)
Gender Women 444 (59.3) 134 (76.1) 1 1
Men 308 (40.7) 42 (23.9) 0.46 (0.31–0.67) 0.36 (0.23–0.55)
TB at initiation No 626 (82.7) 155 (88.1) 1
Yes 131 (17.3) 21 (11.9) 0.65 (0.40–1.01)
WHO stage 1 or 2 or 3 697 (92.1) 163 (92.6) 1
4 60 (7.9) 13 (7.4) 0.92 (0.50–1.73)
CD4* .201 392 (52.1) 93 (55.0) 1 1
200-101 198 (26.8) 35 (20.7) 0.75 (0.49–1.14) 0.74 (0.47–1.17)
100-51 74 (10.0) 16 (9.5) 0.91 (0.51–1.64) 1.35 (0.72–2.53)
#50 74 (10.0) 25 (14.8) 1.42 (0.86–2.36) 2.35 (1.33–4.16)
*26 missing values.
doi:10.1371/journal.pone.0017609.t002
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associated with a CrCl ,50 ml/min. (The relatively high baseline
CD4 compared to other cohorts in southern Africa [13] is explained
by the fact that Lesotho adopted guidelines for early initiation at CD4
,350 cells/uL in 2007.) These associations were used to develop
algorithms that may reduce the numbers needing screening whilst
limiting the risk of missing patients who may be at risk if given TDF.
However, our study was limited by the limited number of baseline
variables available for analysis; other studies have found that low
hemoglobin (Hb,8) and body mass index (BMI,16) were associated
with abnormal baseline renal function, in addition to older age and
lower CD4 [10]. We plan to undertake additional studies including a
broader range of covariates. Further multivariate analyses are needed
to better define cost-effective and resource-appropriate algorithms to
decide on the need for baseline renal monitoring to be carried out,
including a broad range of potential risk factors such as diabetes,
hypertension, and hepatitis co-infection. Such algorithms may aid
policy makers to more clearly balance the cost of creatinine screening
against the risks of missing cases more susceptible to toxicity.
In this community cohort, creatinine monitoring was not
consistent and the accuracy of the calculation was poor. Implemen-
tation ofTDF at primary carefacilitiesinwhich lesser-trained health
cadres will be responsible for routine care provision thus needs to be
accompanied by either simplified visual tools for assessing the CrCl
or by protocols to ensure that the calculation is performed
electronically at the laboratory. In general, renal function improved
on TDF and renal toxicity associated with TDF in our cohort was
rare and mild. Only one case of incident severe renal impairment
was reported, while among those patients who initiated TDF despite
baseline renal impairment, there were no cases of further
deterioration in renal function. A recent meta-analysis of 17 studies
(10889 participants) found that TDF use was associated with a
statistically significant loss of renal function compared to non-TDF
containing regimens, but that the clinical magnitude of this effect
was modest [14]. These findings are consistent with post marketing
(industry sponsored) adverse-event surveillance which found that
0.2% of patients on TDF developed severe renal dysfunction. In
Zambia, where TDF has been adopted as the preferred first-line
since mid-2007, less than 3% of patients initiating TDF are reported
to have had a CrCl decline to ,50 ml/min [15]. Likewise, data
from the DART trial [16], a prospective randomised clinical trial
conducted in an African setting, showed a low (1.3%) rate of severe
renal impairment through 96 weeks, with no difference in TDF-
containing and non TDF-containing regimens.
The management of TDF toxicity in resource-limited settings,
where care is often delivered by lesser-trained health staff at the
primary care level, needs to be carefully defined to avoid both
unnecessary switches or prolonged exposure to potential toxicity.
In our cohort, the majority of those who developed a CrCl
,50 ml/min dropped by less than 10 ml/min and subsequently
returned above the threshold. Similarly, a proportion of those who
dropped to 40–50 ml/min may have been unnecessarily switched
if renal function had been rechecked after treating factors causing
acute renal impairment such as diarrhoea, vomiting, or a urinary
tract infection. Whil the use of TDF without dose reduction
strategies in patients with a CrCl ,50 ml/min needs further
study, outcomes for those who were started on TDF in error with
CrCl ,50 ml/min in our programme are reassuring for
programmes considering TDF-initiation without baseline renal
assessment.
The strength of our study lies in the fact that we used data from a
routine programme setting in an established programme, which
provides a useful compliment to data derived from more controlled
and better resourced research settings. However, the use of
operational data comes at a cost of missing data and a limited
number of covariates for analysis. Our study was further limited by
thelackofconsensusregardingwhichformula touse to calculatethe
CrCl (Cockcroft Gault vs MDRD) and compare with the gold
standard [17–18]. Further research is needed to resolve this issue.
In summary, our study lends further evidence to previous
reports from Africa that TDF-associated renal toxicity is rare and
is in many cases a transient concern. Further studies to assess the
safety of use of TDF at lower CrCl thresholds should be
undertaken. The use of an evidence-based algorithm to rationalise
the use of creatinine screening at baseline may serve as an
important practical tool in countries choosing to switch to a TDF-
based first line where resources for laboratory monitoring may be
limited. Given the low levels of toxicity observed in this and other
clinical settings, and considering the burden and cost of laboratory
monitoring in under-resourced, high HIV-burden settings, the
possibility of TDF implementation without any form of renal
monitoring should not be ruled out.
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Table 3. Algorithms for baseline screening of creatinine.
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 Scenario 6
No creatinine for
individuals ,30
and CD4.200
No creatinine for
individuals ,35
and CD4 .200
No creatinine for
individuals ,40
and CD4.200
No creatinine for
individuals ,30
and CD4.100
No creatinine for
individuals ,35
and CD4.100
No creatinine for
individuals ,40
and CD4.100
Individuals missed
with Creatinine
clearance,50 (%)
3 (1.8%) 10 (5.9%) 14 (8.3%) 4 (2.4%) 14 (8.3%) 19 (11.2%)
Number of individuals
who would not need
to be screened for Cr
clearance (%)
87 (9.6%) 162 (17.8%) 227 (25.0%) 120 (13.2%) 231 (25.5%) 333 (36.8%)
doi:10.1371/journal.pone.0017609.t003
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